Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

Arthritis & Rheumatism ◽

10.1002/art.34580 ◽

2012 ◽

pp. n/a-n/a ◽

Author(s):

Georg Schett ◽

Jurgen Wollenhaupt ◽

Kim Papp ◽

Rik Joos ◽

Jude F. Rodrigues ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0218 Efficacy and safety results of guselkumab, an anti-il23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study

10.1136/annrheumdis-2017-eular.1164 ◽

2017 ◽

Author(s):

A Deodhar ◽

A Gottlieb ◽

W-H Boehncke ◽

B Dong ◽

Y Wang ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Ustekinumab in active psoriatic arthritis including patients previously treated with anti–tumor necrosis factor agents: Week 24 results from PSUMMIT 2, a phase III, multicenter, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.895 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB217

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Previously Treated ◽

Necrosis Factor

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

SAT0271 Continued Improvement of Signs and Symptoms in Ustekinumab-Treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1996 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A674.2-A675

Author(s):

A. Kavanaugh ◽

I. B. McInnes ◽

A. B. Gottlieb ◽

L. Puig ◽

P. Rahman ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Signs And Symptoms ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Fumaric Acid Therapy for Psoriatic Arthritis. A Randomized, Double-blind, Placebo-controlled Study

Rheumatology ◽

10.1093/rheumatology/31.7.502 ◽

1992 ◽

Vol 31 (7) ◽

pp. 502-504 ◽

Author(s):

A. J. PEETERS ◽

B. A. C. DUKMANS ◽

J. G. VAN DER SCHROEFF

Keyword(s):

Psoriatic Arthritis ◽

Fumaric Acid ◽

Controlled Study ◽

Double Blind ◽

Acid Therapy ◽

Double Blind Placebo

Download Full-text

THU0414 Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1806 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 347.2-348 ◽

Author(s):

D. van der Heijde ◽

R. Landewé ◽

P. Mease ◽

I.B. McInnes ◽

P.G. Conaghan ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Radiographic Progression ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2178 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 345.3-346 ◽

Author(s):

A. Kavanaugh ◽

I.B. McInnes ◽

S. Hall ◽

H. Chinoy ◽

A. Kivitz ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2276 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 351.1-351 ◽

Author(s):

B. Kirkham ◽

I.B. McInnes ◽

P. Mease ◽

J. Kremer ◽

S. Kandala ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multiple Measures ◽

Download Full-text

OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.3096 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 136.1-136 ◽

Author(s):

A. Kavanaugh ◽

L. Puig ◽

A.B. Gottlieb ◽

C. Ritchlin ◽

Y. You ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Joint Involvement ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis

Arthritis & Rheumatism ◽

10.1002/anr.1780320208 ◽

1989 ◽

Vol 32 (2) ◽

pp. 158-165 ◽

Author(s):

Simon Carette ◽

Andrei Calin ◽

Jim P. McCafferty ◽

Bruce A. Wallin ◽

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text